Alpelisib (ALP) plus endocrine therapy (ET) by last prior therapy in patients (pts) with PIK3CA-mutated hormone-receptor positive (HR plus ) human epidermal growth factor receptor-2-Negative (HER2-) advanced breast cancer (ABC): Additional study cohort in BYLieve

被引：0

作者：

Ciruelos, E. ^{[1
]}

Lerebours, F. ^{[2
]}

Ruiz Borrego, M. ^{[3
]}

Bachelot, T. ^{[4
]}

Polikoff, J. ^{[5
]}

Chia, S. ^{[6
]}

Juric, D. ^{[7
]}

Turner, N. ^{[8
,9
]}

Ridolfi, A. ^{[10
]}

Sophos, N. ^{[11
]}

Cooper, B. ^{[12
]}

Thuerigen, A. ^{[13
]}

Rugo, H. S. ^{[14
]}

机构：

[1] Univ Hosp 12 Octubre, Med Oncol, Madrid, Spain

[2] Hop Rene Huguenin, Dept Oncol, Inst Curie, St Cloud, France

[3] Hosp Univ Virgen del Rocio, Dept Oncol, Seville, Spain

[4] Ctr Leon Berard, Dept Oncol, Lyon, France

[5] Kaiser Permanente Southern Calif, Dept Oncol, San Diego, CA USA

[6] Univ British Columbia, Dept Med, Vancouver, BC, Canada

[7] Massachusetts Gen Hosp, Dept Oncol, Boston, MA 02114 USA

[8] Inst Canc Res, Dept Oncol, London, England

[9] Royal Marsden Hosp, London, England

[10] Novartis Pharmaceut, Rueil Malmaison, France

[11] Novartis Pharmaceut, Global Oncol, E Hanover, NJ USA

[12] Novartis Pharmaceut, Oncol Med Affairs, E Hanover, NJ USA

[13] Novartis Pharmaceut, Oncol Med Affairs, Basel, Switzerland

[14] UCSF Helen Diller Family Comprehens Canc Ctr, Breast Canc Ctr, San Francisco, CA USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

388TiP

引用

页码：141 / 141

页数：1

共 50 条

[41] Patients' preferences for postmenopausal hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer treatments in Japan
Omori, Y.
Enatsu, S.
Cai, Z.
Ishiguro, H.
CANCER RESEARCH, 2019, 79 (04)
[42] INAVO121: Phase III study of inavolisib (INAVO) plus fulvestrant (FUL) vs. alpelisib (ALP) plus FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2-) PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC)
Juric, Dejan
Kalinsky, Kevin
Im, Seock-Ah
Ciruelos, Eva M.
Bianchini, Giampaolo
Barrios, Carlos H.
Jacot, William
Schmid, Peter
Loi, Sherene
Rugo, Hope S.
Craine, Veronica
Hutchinson, Katherine E.
Flechais, Aulde
Thanopoulou, Eirini
Harbeck, Nadia
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[43] INAVO121: Phase III study of inavolisib (INAVO) plus fulvestrant (FUL) vs. alpelisib (ALP) plus FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2-), PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC)
Juric, Dejan
Kalinsky, Kevin
Im, Seock-Ah
Ciruelos, Eva
Bianchini, Giampaolo
Barrios, Carlos H., Sr.
Jacot, William
Schmid, Peter
Loi, Sherene
Rugo, Hope S.
Craine, Veronica
Hutchinson, Katherine E.
Flechais, Aulde
Thanopoulou, Eirini
Harbeck, Nadia
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[44] Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer
Sarah E. Burnette
Emily Poehlein
Hui-Jie Lee
Jeremy Force
Kelly Westbrook
Heather N. Moore
Breast Cancer Research and Treatment, 2023, 197 : 369 - 376
[45] Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer
Burnette, Sarah E.
Poehlein, Emily
Lee, Hui-Jie
Force, Jeremy
Westbrook, Kelly
Moore, Heather N.
BREAST CANCER RESEARCH AND TREATMENT, 2023, 197 (02) : 369 - 376
[46] Everolimus plus exemestane for hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2
Piccart, M.
Hortobagyi, G. N.
Campone, M.
Pritchard, K. I.
Noguchi, S.
Rugo, H.
Gnant, M.
Feng, W.
Taran, T.
Baselga, J.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : S1 - S1
[47] Efficacy and safety of palbociclib plus fulvestrant in Asian women with hormone receptor-positive (HR plus )/human epidermal growth factor-2 negative (HER2-) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (ET)
Ro, J.
Im, S-A.
Masuda, N.
Im, Y-H.
Inoue, K.
Rai, Y.
Nakamura, R.
Kim, J. H.
Zhang, K.
Giorgetti, C.
Schnell, P.
Bartlett, C. Huang
Iwata, H.
ANNALS OF ONCOLOGY, 2015, 26 : 16 - 16
[48] Longitudinal circulating tumor DNA (ctDNA) analysis in the phase 1b MONALEESASIA study of ribociclib (RIB) plus endocrine therapy (ET) in Asian patients (pts) with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)
Yap, Y. S.
Su, F.
Joshi, M.
Chiu, J.
Masuda, N.
Ito, Y.
Ishikawa, T.
Aruga, T.
Kim, S. J.
Deore, U.
Babbar, N.
Balbin, A.
ANNALS OF ONCOLOGY, 2021, 32 : S459 - S460
[49] NATALEE: Phase III study of ribociclib (RIBO) plus endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).
Slamon, Dennis J.
Fasching, Peter A.
Patel, Ravindranath
Verma, Sunil
Hurvitz, Sara A.
Chia, Stephen K. L.
Crown, John
Martin, Miguel
Barrios, Carlos H.
Spera, Gonzalo
Lopez, Celine
Hor, Ines
Pelov, Diana
Hughes, Gareth
Nawinne, Moditha
Hortobagyi, Gabriel N.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[50] Ribociclib (RIBO) plus letrozole (LET) in patients (pts) with hormone receptorpositive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial.
DeLaurentiis, Michelino
Neven, Patrick
Jerusalem, Guy Heinrich Maria
Bachelot, Thomas Denis
Jacot, William
Dent, Susan Faye
Colleoni, Marco
Prat, Aleix
Martin, Miguel
Ring, Alistair E.
Cottu, Paul H.
Lu, Janice M.
Azim, Hamdy A.
Zhou, Katie
Wu, Jiwen
Zarate, Juan Pablo
Zamagni, Claudio
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →